C-substituted macrocycles as candidates for radioimmunotherapy

被引：35

作者：

Bernhardt, PV ^{[1
]}

Sharpe, PC ^{[1
]}

机构：

[1] Univ Queensland, Dept Chem, Brisbane, Qld 4072, Australia

来源：

INORGANIC CHEMISTRY | 2000年 / 39卷 / 18期

关键词：

D O I：

10.1021/ic000315f

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

The reaction between aryl aldehydes, the macrocyclic ligand 6-methyl-1,4,8,11-tetraazacyclotetradecane-6-amine (L-1), and NaBH3CN produces the corresponding benzyl-substituted ligands in good yield. Copper(II) complexes of the ligands derived from salicylaldehyde (L-2), p-hydroxybenzaldehyde (L-4), and p-carboxybenzaldehyde (L-5) were structurally characterized: [CuL2](ClO4)(2). 3H(2)O (monoclinic, P2(1)/c, a = 11.915(6) Angstrom, b = 13.861(2) Angstrom, c = 17.065(8) Angstrom, beta = 102.14(2)degrees, Z = 4); [CuL4](ClO4)(2) (monoclinic, P2(1)/n, a = 9.550(3) Angstrom, b = 17.977(2) Angstrom, c = 14.612(4) Angstrom, beta 96.76(1)degrees, Z = 4), and [CuL4](ClO4)(2) (monoclinic, P2(1)/n, a = 9.286(2) Angstrom, b = 11.294(1) Angstrom, c = 23.609(8) Angstrom, beta 93.68(1)degrees, Z = 4). Conjugation of several Cu-II complexes to a protein (bovine serum albumin) has been pursued with a view to the application of these macrocycles as bifunctional chelating agents in radioimmunotherapy.

引用

页码：4123 / 4129

页数：7

共 59 条

[1] Structurally reinforced tetraazamacrocyclic complexes [J].

Bernhardt, PV ;

Sharpe, PC .

INORGANIC CHEMISTRY, 2000, 39 (10) :2020-2025

[2] Nitrogen- and carbon-based isomerism in the copper(II) complexes of 6,13-dimethyl-1,4,8,11-tetraazacyclotetradecane-6,13-diamine [J].

Bernhardt, PV ;

Jones, LA ;

Sharpe, PC .

JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1997, (07) :1169-1175

[3] Metal-centred versus ligand-centred luminescence quenching of a macrocyclic copper(II) complex [J].

Bernhardt, PV ;

Flanagan, BM ;

Riley, MJ .

JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1999, (20) :3579-3584

[4]

BERNHARDT PV, UNPUB INORG CHEM

[5] Copper radionuclides and radiopharmaceuticals in nuclear medicine [J].

Blower, PJ ;

Lewis, JS ;

Zweit, J .

NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (08) :957-980

[6] MALIGNANT ASTROCYTOMAS TREATED WITH I-125 LABELED MONOCLONAL-ANTIBODY 425 AGAINST EPIDERMAL GROWTH-FACTOR RECEPTOR - A PHASE II TRIAL [J].

BRADY, LW ;

MIYAMOTO, C ;

WOO, DV ;

RACKOVER, M ;

EMRICH, J ;

BENDER, H ;

DADPARVAR, S ;

STEPLEWSKI, Z ;

KOPROWSKI, H ;

BLACK, P ;

LAZZARO, B ;

NAIR, S ;

MCCORMACK, T ;

NIEVES, J ;

MORABITO, M ;

ESHLEMAN, J .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (01) :225-230

[7] Preparation of the novel chelating agent N-(2-aminoethyl)-trans-1,2-diaminocyclohexane-N,N',N''-pentaacetic acid (H(5)CyDTPA), a preorganized analogue of diethylenetriaminepentaacetic acid (H(5)DTPA), and the structures of Bi-III(CyDTPA)(2-) and Bi-III(H(2)DTPA) complexes [J].

Brechbiel, MW ;

Gansow, OA ;

Pippin, CG ;

Rogers, RD ;

Planalp, RP .

INORGANIC CHEMISTRY, 1996, 35 (21) :6343-&

[8] STRUCTURE AND SOLUTION STABILITY OF INDIUM AND GALLIUM COMPLEXES OF 1,4,7-TRIAZACYCLONONANETRIACETATE AND OF YTTRIUM COMPLEXES OF 1,4,7,10-TETRAAZACYCLODODECANETETRAACETATE AND RELATED LIGANDS - KINETICALLY STABLE COMPLEXES FOR USE IN IMAGING AND RADIOIMMUNOTHERAPY - X-RAY MOLECULAR-STRUCTURE OF THE INDIUM AND GALLIUM COMPLEXES OF 1,4,7-TRIAZACYCLONONANE-1,4,7-TRIACETIC ACID [J].

BROAN, CJ ;

COX, JPL ;

CRAIG, AS ;

KATAKY, R ;

PARKER, D ;

HARRISON, A ;

RANDALL, AM ;

FERGUSON, G .

JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1991, (01) :87-99

[9]

CALLIGARIS M, 1987, COMPREHENSIVE COORDI, V2, P730

[10]

COLE WC, 1987, J NUCL MED, V28, P83

← 1 2 3 4 5 6 →